Related Experiment Videos
An update on gain-of-function mutations in primary immunodeficiency diseases
Rekha D Jhamnani1, Sergio D Rosenzweig
1aNational Institutes of Allergy and Infectious Diseases bDepartment of Laboratory Medicine, Immunology Service, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Current Opinion in Allergy and Clinical Immunology
|October 18, 2017
Summary
Gain-of-function mutations are increasingly recognized as a cause of primary immunodeficiencies, leading to immune dysregulation. This review details their pathophysiology and emerging targeted therapies for better patient outcomes.
Area of Science:
- Immunology
- Genetics
- Molecular Biology
Background:
- Primary immunodeficiencies (PIDs) were historically linked to loss-of-function defects.
- Advancements in next-generation sequencing and functional validation have identified numerous gain-of-function mutations causing PIDs.
Purpose of the Study:
- To review updated pathophysiology mechanisms of PIDs caused by gain-of-function mutations.
- To highlight novel therapeutic strategies for these conditions.
Main Methods:
- Literature review of recent developments in gain-of-function PIDs.
- Analysis of pathophysiology, mutation types, clinical features, and treatments for specific genetic defects.
Main Results:
- Gain-of-function mutations in genes like CARD11, STAT1, STAT3, PIK3CD, PIK3R1, CXCR4, and NFKB2 are associated with increased infection susceptibility, immune dysregulation, and autoimmunity.
- Detailed review of disease-specific updates for each mutation type.
Conclusions:
- Identification of gain-of-function mutations expands understanding of PID genetic mechanisms.
- New targeted therapeutic approaches offer potential rescue treatments for these PIDs.